Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide vs investigator's choice in relapsed or refractory diffuse large B-cell lymphoma
2009-013483-38Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall response rate (Stage 1). Started Apr 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-013483-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013483-38.